Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience

Authors :: Maria Bernardetta Aloi
Mariacristina Di Marco
Francesca Bergamo
A. Iop
Paola Bertocchi
Vittorina Zagonel
Antonio Febbraro
Gianna Musettini
Giovanni Re
Alberto Zaniboni
Davide Melisi
Guido Giordano
Ferdinando De Vita
Enrico Vasile
Alessandro Passardi
Elisa Giommoni
Michele Milella
Luisa Foltran
Vanja Vaccaro
Silvia Vecchiarelli
Source :: Journal of Clinical Oncology. 34:4124-4124
Publication Year :: 2016
Publisher :: American Society of Clinical Oncology (ASCO), 2016.
Abstract: 4124Background: There is no standard of care for 2L T in APDAC. Nab-P + G combination has showed superior efficacy compared to G alone in MPACT phase III study. Here we report data of a retrospecti...

Subjects :: Oncology
Cancer Research
medicine.medical_specialty
Standard of care
Second line treatment
business.industry
First line
medicine.disease
Gemcitabine
03 medical and health sciences
0302 clinical medicine
030220 oncology & carcinogenesis
Internal medicine
Pancreatic cancer
medicine
030211 gastroenterology & hepatology
business
Nab-paclitaxel
medicine.drug

Tools